Precision Medicine in Oncology® | Specialty

Dr. Yang Discusses the Future of Lung Cancer Treatment

September 10th 2014

James CH Yang, MD, PhD, from the National Taiwan University Hospital, discusses the future of lung cancer treatment.

Veliparib Active in Patients with BRCA-Positive Breast, Ovarian Tumors

September 6th 2014

The PARP inhibitor veliparib exhibits antitumor activity and is safe and tolerable on a continuous dosing schedule when used for the treatment of patients with BRCA-positive and BRCA-wild type tumors.

Patient-Derived Xenograft (PDX) Models as Avatars for Patient Response to Therapy

September 3rd 2014

The promise of personalized medicine in cancer will only be met once physicians have both the arsenal of therapeutics they need and a more complete understanding of genomic tumor profiles.

"Angelina Jolie Effect" Sparks More BRCA Testing at Cancer Center

September 2nd 2014

The actress Angelina Jolie's decision to undergo a preventive double mastectomy after learning she carried the BRCA1 gene mutation-associated with an increased risk of breast and/or ovarian cancer-apparently sparked an "Angelina effect" on public health.

Dr. Isaacs on the Importance of Genetic Counseling

September 2nd 2014

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the importance of genetic counseling and the role of the genetic counselor

Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study

August 30th 2014

Robert Petit, PhD, the chief scientific officer at Advaxis, provides insight into the ADXS-PSA immunotherapy and the rationale behind the combination study with pembrolizumab.

Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder Cancer

August 27th 2014

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

Pharma Collaborations Abound Across Oncology

August 21st 2014

A number of large pharmaceutical companies have forged clinical trial collaborations focused on the investigation of novel combinations and companion diagnostics across multiple cancer indications.

Genes That Drive Clear-Cell RCC Discovered, Providing Research Clues

August 21st 2014

A genomic analysis of renal cell carcinoma (RCC) has uncovered new clues about the development, growth, and spread of the cancer.

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

August 18th 2014

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Dr. Stuart on Risks of Phase I Liver Dysfunction Studies

August 14th 2014

Selena Juarez Stuart, MD, hematology/oncology fellow, Cancer Therapy & Research Center, The University of Texas Health Science Center at San Antonio, discusses the risks and benefits of phase I liver dysfunction studies.

Dr. Allen Discusses CO-1686 as a Treatment for Lung Cancer

August 13th 2014

Andrew R. Allen, BM, BCh, MA, MRCP, PhD, Executive Vice President of Clinical and Pre-Clinical Development, Chief Medical Officer, Co-Founder, Clovis Oncology, provides an overview of CO-1686.

Research Leader Looks Beyond Genetic Mechanisms of Acquired Resistance to TKI Therapies

August 12th 2014

Settlemen addressed broad questions about his research into acquired resistance mechanisms in an interview with OncologyLive.

Two-Part Series to Explore Use of Biomarkers in GU Cancer Treatment

August 12th 2014

When it comes to the personalized treatment of genitourinary cancers, biomarkers hold an immense amount of promise. Already, there are predictive and prognostic tools available to urologists.

Dr. Gandara Discusses Third-Generation EGFR TKIs

August 11th 2014

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

The Pivotal Role of Cooperative Group Trials

August 8th 2014

Managing Toxicities Associated With Regorafenib

August 8th 2014

Case Studies in Advanced Colorectal Cancer

August 8th 2014

Optimal Dosing of Regorafenib in CRC

August 8th 2014

Treatment Options for Advanced CRC

August 8th 2014